Defiance ETFs introduced the Defiance Autism Impact ETF (ASD) on Wednesday, a fund that invests in publicly traded companies developing products and services for individuals with autism spectrum disorder and related neurodevelopmental conditions. The issuer describes ASD as the first exchange-traded fund to offer targeted exposure to this theme.
The ETF will donate 100% of its net profits during the first two years to autism-focused nonprofit organizations. After that period, Defiance plans to contribute at least 50% of annual net profits, according to a company statement.
Sylvia Jablonski, chief investment officer at Defiance ETFs, said the fund was inspired by the personal experience of founder and CEO Matthew Bielski and General Counsel Gabriella Zahn-Bielski, whose son has autism. “Like millions of families, they have experienced firsthand both the challenges and opportunities that come with navigating therapies, education, healthcare, and support systems for a child with autism,” she said. That led to the question of whether investors could gain exposure to companies improving lives for those with autism while supporting innovation.
ASD tracks the VettaFi Autism Impact Index using a replication strategy. As of June 3, the index’s top holdings included BrightSpring Health Services Inc. (BTSG), Maplight Therapeutics Inc. (MPLT), Jazz Pharmaceuticals PLC (JAZZ), Revvity Inc. (RVTY), and Stride Inc. (LRN). The fund focuses on companies driving advancements in diagnostics, therapies, educational tools, assistive technologies, and healthcare solutions.
Jablonski noted that the total addressable market for autism-related services could reach $1 trillion. “We’ve heard a lot of interest from pensions, endowments and asset managers seeking exposure to this theme,” she said. The fund also taps into a secular trend as diagnosis rates and support programs expand, potentially boosting demand for products and services in healthcare, education, and technology.
According to Autism Speaks, about 4 in 100 boys and 1 in 100 girls in the U.S. have autism, and 1 in 45 adults are on the spectrum. Jablonski emphasized that the need for services and innovative solutions continues to grow, making the fund relevant for advisors and investors alike. “Nearly everyone knows a family member, friend, colleague, or child who has been touched by autism or neurodivergence,” she said.
Defiance ETFs, founded in 2018, now manages more than 75 ETFs and over $13.4 billion in assets under management. The broader ETF industry has seen explosive growth, with U.S. ETFs accumulating $1.48 trillion in inflows in 2025, surpassing the prior year’s record of $1.1 trillion, according to TD Securities. New ETF launches also hit a record last year, with 1,110 funds coming to market, up from 739 in 2024.
For advisors seeking impact-oriented investments, ASD offers a way to align portfolios with values while participating in a growing niche. The fund’s charitable component may appeal to clients interested in measurable social outcomes. As Jablonski put it, “ASD provides an opportunity to participate in innovation while investing in businesses working to improve outcomes for individuals and families navigating autism.”
Related reading: Pacer ETFs Launches Two AI-Driven Equity Funds Tracking S&P 3AI Indices and VanEck Launches WARP ETF Tracking Space Industry, Targeting $1.8 Trillion Economy by 2035.
